Skip to Content

Generic Humalog Mix 75/25 KwikPen Availability

See also: Generic Humalog Mix 50/50, Generic Humalog Mix 50/50 KwikPen, Generic Humalog Mix 75/25

Humalog Mix 75/25 KwikPen is a brand name of insulin lispro/insulin lispro protamine, approved by the FDA in the following formulation(s):

HUMALOG MIX 75/25 KWIKPEN (insulin lispro protamine recombinant; insulin lispro recombinant - injectable;injection)

  • Manufacturer: LILLY
    Approval date: September 6, 2007
    Strength(s): 75 UNITS/ML;25 UNITS/ML [RLD]

Has a generic version of Humalog Mix 75/25 KwikPen been approved?

No. There is currently no therapeutically equivalent version of Humalog Mix 75/25 KwikPen available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 75/25 KwikPen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Medication dispensing apparatus with triple screw threads for mechanical advantage
    Patent 7,291,132
    Issued: November 6, 2007
    Inventor(s): DeRuntz; Otto Daniel & Focht; Kenneth Allen & Jacobs; Alexander Thomas & Johansen; Elizabeth Whitney & Judson; Jared Alden
    Assignee(s): Eli Lilly and Company

    A medication dispensing apparatus that provides a mechanical advantage. During dose preparing, a nut rotating element (410) and a screw element (368) are in a first axial arrangement such that a screwing motion of the nut rotating element and screw element relative to the apparatus housing that moves the elements a first axial distance from a home position screws a nut (364) along a drive member threaded shaft (362) a second axial distance different than the first axial distance. During dose dispensing, the nut rotating element and the screw element are in a second axial arrangement, whereby a screwing motion of the screw element relative to the housing back toward the home position advances a plunger (366) in the distal direction to axially advance the nut and thereby the drive member and a fluid container piston to dispense medicine.

    Patent expiration dates:

    • August 9, 2024
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about Humalog Mix 75/25 KwikPen (insulin lispro / insulin lispro protamine)

Consumer resources

Other Formulations

Related treatment guides

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.